Noninvasive detection of acquired MET amplification as a mechanism of afatinib/trastuzumab resistance using cfDNA. Noninvasive detection of acquired MET.

Slides:

Advertisements

Similar presentations

© Copyright 2003 Cardinal Health, Inc. or one of its subsidiaries. All rights reserved. PET in Breast Cancer Early detection of disease Precise Staging.

Advertisements

Functional Imaging with PET for Sarcoma Rodney Hicks, MD, FRACP Director, Centre for Molecular Imaging Guy Toner, MD, FRACP Director, Medical Oncology.

Dan Spratt, MD Department of Radiation Oncology Neuroendocrine Prostate Cancer: FDG-PET and Targeted Molecular Imaging.

PET in Colorectal Cancer. Indications for FDG PET Rising marker, (-) CT/MRI Nonspecific findings on CT/MRI, recurrence or post treatment changes? Known.

University of Pennsylvania Department of Orthopaedic Surgery Joseph King, Eileen Crawford, Abass Alavi, Arthur Staddon, Lee Hartner, Richard Lackman and.

Fig FDG PET-CT in patient with cutaneous T-cell lymphoma with treatment response. Baseline (A) and post treatment (B) axial fused PET-CT images demonstrate.

Radiotherapy treatment planning and long-term follow-up with [11C]methionine PET in patients with low-grade astrocytoma Joanne Nuutinen, M.D., Pirkko.

Copyright © 2011 American Medical Association. All rights reserved.

Clonal evolution of resistance to sequential ALK inhibitor therapy.

Figure 1 Carotid artery inflammation detected using 18F-FDG-PET

The Comparison of Computed Tomography Perfusion, Contrast-Enhanced Computed Tomography and Positron-Emission Tomography/Computed Tomography for the Detection.

A, baseline and 4-week PET scan from patient 2 (MET c

Volume 65, Issue 4, Pages (April 2014)

18F-FDG uptake is a noninvasive biomarker of combined MEK–mTORC1 inhibition. 18F-FDG uptake is a noninvasive biomarker of combined MEK–mTORC1 inhibition.

Volume 46, Issue 2, Pages (February 2017)

Emergence of resistance to immune checkpoint blockade is associated with elimination of mutation-associated neoantigens by LOH and a more diverse T-cell.

Intrinsic and acquired trastuzumab resistance.

Otolaryngology referred this patient for imaging after palpating a mass in the “left parotid tail.” Axial contrast-enhanced CT scan through the mass reveals.

Identification of a MEK2 mutation in a melanoma sample resistant to dabrafenib/trametinib. Identification of a MEK2 mutation in a melanoma sample resistant.

Unexpected Small Bowel Intussusception Caused by Lung Cancer Metastasis on 18F- Fluorodeoxyglucose PET-CT Jeong Won Lee, MD, Seok-Ki Kim, MD, Ji Won Park,

Successful tissue collection in patients with relapse of EGFR-positive adenocarcinoma after EGFR-TKI treatment. Successful tissue collection in patients.

Example of pretreatment (A and B) and 8-week posttreatment (C and D) PET CT images. Example of pretreatment (A and B) and 8-week posttreatment (C and D)

Capture of CK+ and CK− complex aneuploid CTCs in breast, ovarian, or colorectal cancer. Capture of CK+ and CK− complex aneuploid CTCs in breast, ovarian,

Circulating Tumor DNA Identifies EGFR Coamplification as a Mechanism of Resistance to Crizotinib in a Patient with Advanced MET-Amplified Lung Adenocarcinoma

The impact of 18F-FDG PET-CT scanning for staging and management of Merkel cell carcinoma: Results from Westmead Hospital, Sydney, Australia Rebecca.

Fig. 5. Clinical data with BLU-285 confirm early evidence of activity in patients with diseases driven by KIT and PDGFRA activation loop mutations. Clinical.

Pharmacodynamic effects of PI3K inhibitor NVP-BKM120 on breast carcinomas in MMTV-CreBrca1f/fTrp53+/− mice. Pharmacodynamic effects of PI3K inhibitor NVP-BKM120.

Representative CT and PET/CT images of three patients with NSCLCs

The role of positron emission tomography for non-small cell lung cancer Albert J. Chang, MD, PhD, Farrokh Dehdashti, MD, Jeffrey D. Bradley, MD Practical.

Mechanisms of Acquired Resistance to AZD9291

Matthew Reichert, MD, Eric S. Bensadoun, MD

Fig F-FGln shows uptake in human gliomas undergoing progression.

Treatment and diagnosis history, and response to targeted therapy, of a patient with pancreatic adenocarcinoma with an EGFR exon19 deletion. Treatment.

High-level clonal amplification of FGFR2 predicts for sensitivity to FGFR inhibitor. High-level clonal amplification of FGFR2 predicts for sensitivity.

ALK resistance mutations predict for sensitivity to lorlatinib in patient-derived cell line models of acquired resistance to ceritinib. ALK resistance.

Clinical response to anti-ERBB3 mAb therapy in a patient with an advanced NRG1-rearranged non–small cell lung cancer. Clinical response to anti-ERBB3 mAb.

A and B, Computed tomography (CT) of the chest prior to cabozantinib therapy demonstrated a dominant mass in the left upper lobe (B, black arrow), measuring.

Representative CT and PET/CT images of three patients with NSCLCs

Plasma and tissue EGFR allele analyses.

Serial imaging before and after immunotherapy among patients with MDM2/4 amplifications (N = 6). Serial imaging before and after immunotherapy among patients.

HGSOC mutational processes are established early and are patient-specific. HGSOC mutational processes are established early and are patient-specific. A,

Example inverse FF-OCT images (left column) and corresponding histology images (right column) of ovarian metastases. Example inverse FF-OCT images (left.

Serial chest CT scans of 33-year-old male with lung adenocarcinoma harboring EGFR-KDD documenting response to afatinib and subsequent acquired resistance.

Immunohistochemical staining for FOXO3a of breast cancer tumor tissues

Antitumor activity. Antitumor activity. A, maximum change in target lesion size from baseline assessed according to RECIST 1.0 (n = 26). Six patients had.

Waterfall plot showing the relative change in median tumor FES uptake (SUVcor) in individual patients at the second scan compared with baseline. Waterfall.

A 63-year-old female with lung adenocarcinoma treated with nivolumab, who experienced pseudoprogression. A 63-year-old female with lung adenocarcinoma.

Molecular heterogeneity drives secondary resistance to anti-EGFR therapies in mCRC. Molecular heterogeneity drives secondary resistance to anti-EGFR therapies.

Molecular heterogeneity can drive mixed response and treatment failure in EGC. A, PET images from Patient #4 obtained before treatment and upon disease.

Location of the ER mutations and frequencies per cohort.

Individual treatment outcomes of 20 patients treated with afatinib and 12 patients treated with afatinib and trastuzumab. Individual treatment outcomes.

Change in FES uptake in the tumor during fulvestrant treatment.

Combined inhibition of coamplified RTKs is required for response.

Frequent coamplification of RTKs in MET-amplified EGC

A, pretreatment CT scan of pelvic lymphadenopathy (identified by white arrow) in 1 patient with documented response to 1α-OH-D2. A, pretreatment CT scan.

Representative patient responses to ulixertinib.

Rapid autopsy reveals interlesional and intralesional heterogeneity of resistance. Rapid autopsy reveals interlesional and intralesional heterogeneity.

Representative biodistribution pattern of 111In-CMD-193.

Tracking resistance to TRKA inhibition in ctDNA of a patient with colorectal cancer. Tracking resistance to TRKA inhibition in ctDNA of a patient with.

Serial CT scan images from patient with a partial response.

Response to crizotinib in an 8-year-old boy with refractory IMT harboring a TFG–ROS1 fusion. Response to crizotinib in an 8-year-old boy with refractory.

BRAF in-frame deletion confers response to MAPK inhibition.

SD-101 and low-dose radiation induces responses in patients with indolent lymphoma. SD-101 and low-dose radiation induces responses in patients with indolent.

Concordance between liquid versus tissue biopsies.

Circulating Tumor DNA Identifies EGFR Coamplification as a Mechanism of Resistance to Crizotinib in a Patient with Advanced MET-Amplified Lung Adenocarcinoma

A, Changes in BRAFV600E cfDNA allele fraction from baseline after one dose of treatment for 12 patients with serial samples available, classified according.

Detection of BRCA reversion mutations in pretreatment cfDNA and tumor biopsy. Detection of BRCA reversion mutations in pretreatment cfDNA and tumor biopsy.

Single-site disease progression after 9 months of response to therapy in the right hemipelvis visualized by diffusion-weighted whole-body MRI. Top, fusion.

Response and resistance to savolitinib and osimertinib in a patient with EGFR-mutant NSCLC harboring MET amplification. Response and resistance to savolitinib.

NI-RADS primary site category 2a: superficial mucosal abnormality.

Presentation transcript:

Noninvasive detection of acquired MET amplification as a mechanism of afatinib/trastuzumab resistance using cfDNA. Noninvasive detection of acquired MET amplification as a mechanism of afatinib/trastuzumab resistance using cfDNA. A, Radiographic tumor assessment using 89Zr-trastuzumab PET and conventional CT scan, with corresponding bar graphs in patient 28. 89Zr-trastuzumab PET values in SUV and CT measurements in mm. Left, a baseline pretreatment 89Zr-trastuzumab PET image showing uptake in a left ovary metastasis (SUV 5.1) not visible in this projection, perigastric peritoneal metastasis (SUV 7.2, lower arrow), and gastric mass (SUV 8.2, upper arrow). Right, 89Zr-trastuzumab PET 5 weeks post-treatment initiation, showing resolution of uptake in the perigastric peritoneal metastasis (SUV 1.8) and gastric mass (SUV 3.9) and persistently high uptake in the left ovarian metastasis (SUV 5.2) not seen on maximum intensity projection (MIP) images. B, cfDNA analysis at the time of disease progression on afatinib/trastuzumab, demonstrating ERBB2 and MET amplification (results for additional time points are provided in Supplementary Table S9). C, Genomic comparison of matched pretreatment biopsy with post-treatment tumor tissue collected from the left ovarian metastasis and subsequently at rapid autopsy, demonstrating acquired MET amplification unique to the progressing lesions. The perigastric metastasis (met) and the primary tumor, both of which demonstrated ongoing response to afatinib/trastuzumab, did not harbor MET amplification. D, Dual probe EGFR and ERBB2 FISH from a perirectal tumor biopsy collected after treatment demonstrated ERBB2 amplification and low-level gain of EGFR in a subset of tumor cells. Francisco Sanchez-Vega et al. Cancer Discov 2019;9:199-209 ©2019 by American Association for Cancer Research